Category: Regulatory DisclosuresBy adminOctober 8, 2023 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Disclosure to EGX regarding the appointment of Khaled Daader as Head of Investor Relations and Mergers and AcquisitionsNextNext post:Equinox Pharma Holding Limited (Equinox) increases stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.Related PostsRameda Initiates First Acquisition of 2025July 7, 2025Record Dividend Distribution DisclosureJuly 7, 2025BOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024Rameda 4Q23 BOD Meeting MinutesMarch 18, 2024
